Biomarker & Intervention Discovery
Polycythaemia Vera / Myeloproliferative Neoplasms
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionPV/ET/MF: no spontaneous remission; progressive disorders with risk of transformation to MF (PV/ET) and blast phase…
Best-intervention remissionJAK2 inhibitor (ruxolitinib) for MF/PV: 35-42% spleen volume reduction, significant symptom improvement…
Gap sizeModerate — ruxolitinib is established but HSCT underused in eligible MF patients; ropeginterferon is superior in PV…
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
PV/ET/MF: no spontaneous remission; progressive disorders with risk of transformation to MF (PV/ET) and blast phase (all); median survival PV >20 years, MF 5-7 years
Best-intervention remission
JAK2 inhibitor (ruxolitinib) for MF/PV: 35-42% spleen volume reduction, significant symptom improvement; ropeginterferon alfa-2b: superior complete haematological response vs hydroxyurea (PROUD-PV); allogeneic HSCT (MF): curative in 30-60% of transplant-eligible patients
Gap size
Moderate — ruxolitinib is established but HSCT underused in eligible MF patients; ropeginterferon is superior in PV but access varies
Primary barrier
access/practice
Hydroxyurea remains the most common cytoreductive agent for PV/ET despite ropeginterferon demonstrating superior molecular response; HSCT for MF is underutilised in patients who could benefit; JAK2 mutation molecular monitoring not performed systematically
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Polycythaemia Vera / Myeloproliferative Neoplasms” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."